195 related articles for article (PubMed ID: 28484271)
21. Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers.
Lefaucheur JP; Ng Wing Tin S; Kerschen P; Damy T; Planté-Bordeneuve V
J Neurol; 2013 Jun; 260(6):1497-503. PubMed ID: 23306657
[TBL] [Abstract][Full Text] [Related]
22. Clinical picture and outcome of transthyretin-related familial amyloid polyneuropathy (FAP) in Japanese patients.
Ikeda S
Clin Chem Lab Med; 2002 Dec; 40(12):1257-61. PubMed ID: 12553427
[TBL] [Abstract][Full Text] [Related]
23. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
[TBL] [Abstract][Full Text] [Related]
24. A chemometric approach for characterization of serum transthyretin in familial amyloidotic polyneuropathy type I (FAP-I) by electrospray ionization-ion mobility mass spectrometry.
Pont L; Sanz-Nebot V; Vilaseca M; Jaumot J; Tauler R; Benavente F
Talanta; 2018 May; 181():87-94. PubMed ID: 29426546
[TBL] [Abstract][Full Text] [Related]
25. Electrophysiological parameters that contribute to the pathogenesis of familial amyloid polyneuropathy caused by transthyretin mutations.
Lai HJ; Lai WT; Jin L; Kuo KT; Lee MJ
J Neurol Sci; 2020 Jun; 413():116810. PubMed ID: 32247966
[TBL] [Abstract][Full Text] [Related]
26. [Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
Chaves M; Bettini M; Marciano S; Sáez S; Cristiano E; Rugiero M
Medicina (B Aires); 2016; 76(2):105-8. PubMed ID: 27135849
[TBL] [Abstract][Full Text] [Related]
27. A non-invasive method based on saliva to characterize transthyretin in familial amyloidotic polyneuropathy patients using FT-ICR high-resolution MS.
da Costa G; Guerreiro A; Correia CF; Gomes RJ; Freire A; Monteiro E; Barroso E; Coelho AV; Outeiro TF; Freire AP; Cordeiro C
Proteomics Clin Appl; 2010 Jul; 4(6-7):674-8. PubMed ID: 21179887
[TBL] [Abstract][Full Text] [Related]
28. Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy.
Sousa MM; do Amaral JB; Guimarães A; Saraiva MJ
FASEB J; 2005 Jan; 19(1):124-6. PubMed ID: 15536164
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.
Takahashi R; Ono K; Shibata S; Nakamura K; Komatsu J; Ikeda Y; Ikeda T; Samuraki M; Sakai K; Iwasa K; Kayano D; Yamada M
J Neurol Sci; 2014 Oct; 345(1-2):231-5. PubMed ID: 25060417
[TBL] [Abstract][Full Text] [Related]
30. The inflammatory response to sciatic nerve injury in a familial amyloidotic polyneuropathy mouse model.
Gonçalves NP; Teixeira-Coelho M; Saraiva MJ
Exp Neurol; 2014 Jul; 257():76-87. PubMed ID: 24800914
[TBL] [Abstract][Full Text] [Related]
31. Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser.
Kan HW; Chiang H; Lin WM; Yu IS; Lin SW; Hsieh ST
Neuropathol Appl Neurobiol; 2018 Dec; 44(7):673-686. PubMed ID: 29423915
[TBL] [Abstract][Full Text] [Related]
32. Familial amyloidotic polyneuropathy and transthyretin.
Nagasaka T
Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic strategy for familial amyloid polyneuropathy (FAP)].
Ikeda S
Rinsho Shinkeigaku; 2009 Nov; 49(11):953-5. PubMed ID: 20030258
[TBL] [Abstract][Full Text] [Related]
34. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y
J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715
[TBL] [Abstract][Full Text] [Related]
35. Follow-up in transthyretin familial amyloid polyneuropathy: Useful investigations.
Escolano-Lozano F; Geber C; Barreiros AP; Birklein F
J Neurol Sci; 2020 Jun; 413():116776. PubMed ID: 32203746
[TBL] [Abstract][Full Text] [Related]
36. Steady turnover of amyloid fibril proteins in gastric mucosa after liver transplantation in familial amyloid polyneuropathy.
Tsuchiya-Suzuki A; Yazaki M; Sekijima Y; Kametani F; Ikeda S
Amyloid; 2013 Sep; 20(3):156-63. PubMed ID: 23826783
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells.
Niemietz CJ; Sauer V; Stella J; Fleischhauer L; Chandhok G; Guttmann S; Avsar Y; Guo S; Ackermann EJ; Gollob J; Monia BP; Zibert A; Schmidt HH
PLoS One; 2016; 11(9):e0161455. PubMed ID: 27584576
[TBL] [Abstract][Full Text] [Related]
38. Serum transthyretin levels in Swedish TTR V30M carriers.
Buxbaum J; Anan I; Suhr O
Amyloid; 2010 Jun; 17(2):83-5. PubMed ID: 20462367
[TBL] [Abstract][Full Text] [Related]
39. A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.
Jimenez-Zepeda VH; Bahlis NJ; Gilbertson J; Rendell N; Porcari R; Lachmann HJ; Gillmore JD; Hawkins PN; Rowczenio DM
Amyloid; 2015 Mar; 22(1):26-30. PubMed ID: 25430583
[TBL] [Abstract][Full Text] [Related]
40. Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach.
Tasaki M; Ueda M; Obayashi K; Koike H; Kitagawa K; Ogi Y; Jono H; Su Y; Suenaga G; Oshima T; Misumi Y; Yoshida M; Yamashita T; Sobue G; Ando Y
Int J Cardiol; 2013 Dec; 170(1):69-74. PubMed ID: 24182678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
